All Stories

  1. RSV nucleoprotein inhibitors in preclinical to phase II clinical development for respiratory syncytial virus infection
  2. Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells
  3. Probenecid Treatment Inhibits Replication of the Edmonston Measles Virus Strain in Vero Cells
  4. Restricting O-Linked Glycosylation of the Mucin-like Domains Enhances Immunogenicity and Protective Efficacy of a Respiratory Syncytial Virus G Glycoprotein Vaccine Antigen
  5. The MAPK Response to Virus Infection Is Modified by Probenecid
  6. Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity
  7. Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs)
  8. Evaluating Probenecid or Oseltamivir Inhibition of Influenza A Virus Replication Through Plaque Assay or Fluorescent Focus Assay Using Non-Structural Protein 1–H1N1 Venus Reporter Virus
  9. Probenecid Inhibits Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase Mitogen-Activated Protein Kinase Pathways in Regulating Respiratory Syncytial Virus Response
  10. Antiviral agents and therapeutics against respiratory viruses
  11. Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice
  12. mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge
  13. Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice
  14. Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication
  15. mRNA Vaccines Encoding Influenza Virus Hemagglutinin (HA) Elicits Immunity in Mice from Influenza A Virus Challenge
  16. Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19
  17. Understanding immunity to influenza: implications for future vaccine development
  18. Interferons—Implications in the Immune Response to Respiratory Viruses
  19. Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
  20. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
  21. Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
  22. RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
  23. Influenza B Virus (IBV) Immune-Mediated Disease in C57BL/6 Mice
  24. Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs
  25. Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
  26. Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
  27. Structural basis for ultrapotent neutralization of human metapneumovirus
  28. ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
  29. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
  30. Immunopathology of RSV: An Updated Review
  31. MicroRNAs affect GPCR and Ion channel genes needed for influenza replication
  32. Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro
  33. Advances in Vaccine Development
  34. Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs
  35. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein
  36. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
  37. Losartan Inhibits SARS-CoV-2 Replication in Vitro
  38. Innate Antiviral Cytokine Response to Swine Influenza Virus by Swine Respiratory Epithelial Cells
  39. Probenecid Inhibits SARS-CoV-2 Replication In Vivo and In Vitro
  40. G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication
  41. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins
  42. Losartan promotes cell survival following SARS-CoV-2 infection in vitro
  43. Innate and adaptive immune responses in respiratory virus infection: implications for the clinic
  44. Exosome-mediated human norovirus infection
  45. Pathobiology of Respiratory Syncytial Virus (RSV)
  46. Regulation of Mumps Virus Replication and Transcription by Kinase RPS6KB1
  47. Up-to-date role of biologics in the management of respiratory syncytial virus
  48. Vero Cells as a Mammalian Cell Substrate for Human Norovirus
  49. Emerging small and large molecule therapeutics for respiratory syncytial virus
  50. Gene-edited vero cells as rotavirus vaccine substrates
  51. Original Antigenic Sin and Respiratory Syncytial Virus Vaccines
  52. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo
  53. Human Norovirus: Experimental Models of Infection
  54. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro
  55. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
  56. Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
  57. Viral Modulation of Host Translation and Implications for Vaccine Development
  58. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
  59. A universal mammalian vaccine cell line substrate
  60. Revisiting the RSV G protein as a target for drugs and vaccines.
  61. MicroRNA-134 regulates poliovirus replication by IRES targeting
  62. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge
  63. The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection
  64. Respiratory syncytial virus: prospects for new and emerging therapeutics
  65. Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome
  66. Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment
  67. Development of improved vaccine cell lines against rotavirus
  68. Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection
  69. Inhaled Countermeasures for Respiratory Tract Viruses
  70. Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus
  71. Passive narcosis for anesthesia induction in cotton rats (Sigmodon hispidus)
  72. Development of a Zika vaccine
  73. MicroRNA-555 has potent antiviral properties against poliovirus
  74. Human Respiratory Syncytial Virus
  75. MicroRNA Profiling from RSV-Infected Biofluids, Whole Blood, and Tissue Samples
  76. Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay
  77. Human Respiratory Syncytial Virus: An Introduction
  78. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis
  79. Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease
  80. An innate defence role for BPIFA1/SPLUNC1 against influenza-A virus infection
  81. Antiviral agents for influenza virus
  82. Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression
  83. Polymerase Discordance in Novel Swine Influenza H3N2v Constellations Is Tolerated in Swine but Not Human Respiratory Epithelial Cells
  84. Can an influenza A-based delivery system overcome current challenges associated with miRNA technology?
  85. Frontiers in RNAi
  86. Preface
  87. List of Contributors
  88. Acknowledgments
  89. Author Index
  90. RNAi Screening to Facilitate Drug Repurposing
  91. Subject Index
  92. The Use of RNAi Technology in the Development of High Performance Bioproduction Cell Lines
  93. Virus-Vectored Influenza Virus Vaccines
  94. Identification of Virulence Determinants in Influenza Viruses
  95. Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication In Vitro and In Vivo
  96. Rapid Identification of Bacterial Pathogens of Military Interest Using Surface-Enhanced Raman Spectroscopy
  97. A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)
  98. Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge
  99. Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets
  100. Addressing the Re-emergence of Poliovirus
  101. Antiviral Effects of Inhibiting Host Gene Expression
  102. Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
  103. Targeting Fungal Genes by Diced siRNAs: A Rapid Tool to Decipher Gene Function in Aspergillus nidulans
  104. Targeting Cell Division Cycle 25 Homolog B To Regulate Influenza Virus Replication
  105. Modeling Respiratory Syncytial Virus Cytopathogenesis in the Human Airway
  106. Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease
  107. Respiratory Syncytial Virus Infection Induces Higher Toll-Like Receptor-3 Expression and TNF-α Production Than Human Metapneumovirus Infection
  108. Viral Etiology and Clinical Profiles of Children with Severe Acute Respiratory Infections in China
  109. Protective Efficacy and Immunogenicity of a Combinatory DNA Vaccine against Influenza A Virus and the Respiratory Syncytial Virus
  110. Methotrexate Treatment Causes Early Onset of Disease in a Mouse Model of Ross River Virus-Induced Inflammatory Disease through Increased Monocyte Production
  111. A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
  112. Gain-of-Function Experiments on H7N9
  113. Gain-of-Function Experiments on H7N9
  114. Advances in and the potential of vaccines for respiratory syncytial virus
  115. A Novel Influenza Virus Hemagglutinin-Respiratory Syncytial Virus (RSV) Fusion Protein Subunit Vaccine against Influenza and RSV
  116. Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 4 Induces Apoptosis Dependent on Its 3C-Like Serine Protease Activity
  117. Antiviral Responses by Swine Primary Bronchoepithelial Cells Are Limited Compared to Human Bronchoepithelial Cells Following Influenza Virus Infection
  118. Broadening the Heterologous Cross-Neutralizing Antibody Inducing Ability of Porcine Reproductive and Respiratory Syndrome Virus by Breeding the GP4 or M genes
  119. Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs
  120. Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse Models of Influenza A Virus Infection
  121. A Mechanistic Study on the Destabilization of Whole Inactivated Influenza Virus Vaccine in Gastric Environment
  122. The Role of Interleukin-1 and Interleukin-18 in Pro-Inflammatory and Anti-Viral Responses to Rhinovirus in Primary Bronchial Epithelial Cells
  123. Bat cells from Pteropus alecto are susceptible to influenza A virus infection and reassortment
  124. Vertical Transmission of Respiratory Syncytial Virus Modulates Pre- and Postnatal Innervation and Reactivity of Rat Airways
  125. Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice
  126. Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection
  127. Avian Influenza Virus Surveillance in Wild Birds in Georgia: 2009–2011
  128. Adenovirus 36, adiposity, and bone strength in late‐adolescent females
  129. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning
  130. Transmission Studies Resume For Avian Flu
  131. Detection and differentiation of foodborne pathogenic bacteria in mung bean sprouts using field deployable label-free SERS devices
  132. Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis
  133. Risk Assessment and Anti-Viral Approaches for Novel H7N9 Influenza Virus
  134. Therapeutic Considerations for Middle East Respiratory Syndrome Coronavirus
  135. Host Gene Expression and Respiratory Syncytial Virus Infection
  136. Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
  137. Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics
  138. Enzymatically Produced Pools of Canonical and Dicer-Substrate siRNA Molecules Display Comparable Gene Silencing and Antiviral Activities against Herpes Simplex Virus
  139. Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy
  140. Highly Sensitive and Transparent Surface Enhanced Raman Scattering Substrates Made by Active Coldly Condensed Ag Nanorod Arrays
  141. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication
  142. Label-Free Detection of Micro-RNA Hybridization Using Surface-Enhanced Raman Spectroscopy and Least-Squares Analysis
  143. Signal 3 Cytokines as Modulators of Primary Immune Responses during Infections: The Interplay of Type I IFN and IL-12 in CD8 T Cell Responses
  144. A New Model for Hendra Virus Encephalitis in the Mouse
  145. Nucleoprotein Nanostructures Combined with Adjuvants Adapted to the Neonatal Immune Context: A Candidate Mucosal RSV Vaccine
  146. MicroRNA Regulation of Human Protease Genes Essential for Influenza Virus Replication
  147. Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains
  148. The use of a handheld Raman system for virus detection
  149. Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose
  150. Differential Expression of Cytokines in Response to Respiratory Syncytial Virus Infection of Calves with High or Low Circulating 25-Hydroxyvitamin D3
  151. Respiratory Syncytial Virus NS1 Protein Colocalizes with Mitochondrial Antiviral Signaling Protein MAVS following Infection
  152. The C Proteins of Human Parainfluenza Virus Type 1 Block IFN Signaling by Binding and Retaining Stat1 in Perinuclear Aggregates at the Late Endosome
  153. Pause on Avian Flu Transmission Research
  154. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens
  155. Flexible and mechanical strain resistant large area SERS active substrates
  156. Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics
  157. Current Progress on Surface-Enhanced Raman Scattering Chemical/Biological Sensing
  158. Surveillance of feral cats for influenza A virus in North Central Florida
  159. Detection and Differentiation of Avian Mycoplasmas by Surface-Enhanced Raman Spectroscopy Based on a Silver Nanorod Array
  160. Porcine FcγRIIb Mediates Enhancement of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Infection
  161. Humoral and Cell-Mediated Immunity to Pandemic H1N1 Influenza in a Canadian Cohort One Year Post-Pandemic: Implications for Vaccination
  162. Human Metapneumovirus: Lessons Learned over the First Decade
  163. Increased MDSC Accumulation and Th2 Biased Response to Influenza A Virus Infection in the Absence of TLR7 in Mice
  164. Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells
  165. Exposed Hydrophobic Residues in Human Immunodeficiency Virus Type 1 Vpr Helix-1 Are Important for Cell Cycle Arrest and Cell Death
  166. Evaluation of Protective Efficacy of Respiratory Syncytial Virus Vaccine against A and B Subgroup Human Isolates in Korea
  167. Influenza-Specific T Cells from Older People Are Enriched in the Late Effector Subset and Their Presence Inversely Correlates with Vaccine Response
  168. The Microbial Detection Array Combined with Random Phi29-Amplification Used as a Diagnostic Tool for Virus Detection in Clinical Samples
  169. Circulating Strains of Human Respiratory Syncytial Virus in Central and South America
  170. Interferon Production and Signaling Pathways Are Antagonized during Henipavirus Infection of Fruit Bat Cell Lines
  171. Immunostimulatory Motifs Enhance Antiviral siRNAs Targeting Highly Pathogenic Avian Influenza H5N1
  172. Avian Influenza Viruses Infect Primary Human Bronchial Epithelial Cells Unconstrained by Sialic Acid α2,3 Residues
  173. Self-Collected Mid-Turbinate Swabs for the Detection of Respiratory Viruses in Adults with Acute Respiratory Illnesses
  174. Influenza A Virus Nucleoprotein Exploits Hsp40 to Inhibit PKR Activation
  175. Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors
  176. Polarity Changes in the Transmembrane Domain Core of HIV-1 Vpu Inhibits Its Anti-Tetherin Activity
  177. Comparative Pathology in Ferrets Infected with H1N1 Influenza A Viruses Isolated from Different Hosts
  178. Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1)
  179. Universal Oligonucleotide Microarray for Sub-Typing of Influenza A Virus
  180. Comparative Pathogenesis of Three Human and Zoonotic SARS-CoV Strains in Cynomolgus Macaques
  181. Viral and Atypical Bacterial Detection in Acute Respiratory Infection in Children Under Five Years
  182. Aerosol Inoculation with a Sub-lethal Influenza Virus Leads to Exacerbated Morbidity and Pulmonary Disease Pathogenesis
  183. Distinct Roles of Cdc42 in Thymopoiesis and Effector and Memory T Cell Differentiation
  184. Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice
  185. A Rapid Flp-In System for Expression of Secreted H5N1 Influenza Hemagglutinin Vaccine Immunogen in Mammalian Cells
  186. Serological Response to the 2009 Pandemic Influenza A (H1N1) Virus for Disease Diagnosis and Estimating the Infection Rate in Thai Population
  187. Detection of Resistance Mutations to Antivirals Oseltamivir and Zanamivir in Avian Influenza A Viruses Isolated from Wild Birds
  188. One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles
  189. Passage of low-pathogenic avian influenza (LPAI) viruses mediates rapid genetic adaptation of a wild-bird isolate in poultry
  190. Application of RNA Interference to Viral Diseases
  191. Effects of Human Respiratory Syncytial Virus, Metapneumovirus, Parainfluenza Virus 3 and Influenza Virus on CD4+ T Cell Activation by Dendritic Cells
  192. Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination
  193. Exploring Cell Tropism as a Possible Contributor to Influenza Infection Severity
  194. Detection of Mycoplasma pneumoniae in Simulated and True Clinical Throat Swab Specimens by Nanorod Array-Surface-Enhanced Raman Spectroscopy
  195. A Metagenomic Analysis of Pandemic Influenza A (2009 H1N1) Infection in Patients from North America
  196. Therapeutic targeting of respiratory syncytial virus G-protein
  197. Enhanced Immunogenicity of Stabilized Trimeric Soluble Influenza Hemagglutinin
  198. The Expression of Vasoactive Intestinal Peptide Receptor 1 Is Negatively Modulated by MicroRNA 525-5p
  199. Monomeric and Dimeric CXCL8 Are Both Essential for In Vivo Neutrophil Recruitment
  200. Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins
  201. Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice
  202. The Proapoptotic Influenza A Virus Protein PB1-F2 Forms a Nonselective Ion Channel
  203. Trafficking of Sendai Virus Nucleocapsids Is Mediated by Intracellular Vesicles
  204. A Single Immunization with Soluble Recombinant Trimeric Hemagglutinin Protects Chickens against Highly Pathogenic Avian Influenza Virus H5N1
  205. Phospholipase D1 Mediates TNFα-Induced Inflammation in a Murine Model of TNFα-Induced Peritonitis
  206. Rapid and Sensitive Detection of Rotavirus Molecular Signatures Using Surface Enhanced Raman Spectroscopy
  207. Respiratory Syncytial Virus F and G Proteins Induce Interleukin 1α, CC, and CXC Chemokine Responses by Normal Human Bronchoepithelial Cells
  208. SERS-based viral fingerprinting: current capabilities and challenges
  209. Immunoproteomics Analysis of the Murine Antibody Response to Vaccination with an Improved Francisella tularensis Live Vaccine Strain (LVS)
  210. Pneumovirus and Metapneumovirus: Respiratory Syncytial Virus and Human Metapneumovirus
  211. Identification of individual genotypes of measles virus using surface enhanced Raman spectroscopy
  212. Label-free SERS detection of microRNA based on affinity for an unmodified silver nanorod array substrate
  213. Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice
  214. Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
  215. Quantitative Surface-Enhanced Raman Spectroscopy Based Analysis of MicroRNA Mixtures
  216. Emerging Technologies in Nanotechnology-Based Pathogen Detection
  217. Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice
  218. Fabrication and characterization of a multiwell array SERS chip with biological applications
  219. Replication and pathogenesis associated with H5N1, H5N2, and H5N3 low-pathogenic avian influenza virus infection in chickens and ducks
  220. RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
  221. Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway
  222. Optimization of a multi-well array SERS chip
  223. Human Metapneumovirus Establishes Persistent Infection in the Lungs of Mice and Is Reactivated by Glucocorticoid Treatment
  224. The host response and molecular pathogenesis associated with respiratory syncytial virus infection
  225. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice
  226. Therapeutic Applications of RNAi for Silencing Virus Replication
  227. Animal Models for Evaluation of Influenza Vaccines
  228. Spherical and Anisotropic Silver Nanomaterials in Medical Diagnosis
  229. Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS)
  230. Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2
  231. Revised model for early memory T-cell protection against respiratory virus challenge
  232. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15)
  233. RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response
  234. Virally Encoded MicroRNA (miRNA) Candidates for Gene Silencing
  235. Molecular and cellular mechanisms in the viral exacerbation of asthma
  236. Novel nanostructures for SERS biosensing
  237. Infectious Agent Detection With SERS-Active Silver Nanorod Arrays Prepared by Oblique Angle Deposition
  238. An Au/Si hetero-nanorod-based biosensor forSalmonelladetection
  239. Identification and classification of respiratory syncytial virus (RSV) strains by surface-enhanced Raman spectroscopy and multivariate statistical techniques
  240. Serum Mannose-Binding Lectin Levels are Linked with Respiratory Syncytial Virus (RSV) Disease
  241. Evasion of Host Immune Responses by Tumours and Viruses
  242. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge
  243. Bioconjugated nanoparticle detection of respiratory syncytial virus infection
  244. An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection
  245. Rapid and Sensitive Detection of Respiratory Virus Molecular Signatures Using a Silver Nanorod Array SERS Substrate
  246. Silver nanorod arrays as highly sensitive SERS substrates for viral detection
  247. Counting Single Native Biomolecules and Intact Viruses with Color-Coded Nanoparticles
  248. Respiratory Syncytial Virus (RSV) Infects Neuronal Cells and Processes That Innervate the Lung by a Process Involving RSV G Protein
  249. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?
  250. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins
  251. Cytokines and Respiratory Syncytial Virus Infection
  252. Real-Time Detection of Virus Particles and Viral Protein Expression with Two-Color Nanoparticle Probes
  253. The Immune Response to Human Metapneumovirus Is Associated with Aberrant Immunity and Impaired Virus Clearance in BALB/c Mice
  254. Corrigendum to “Serological cross-reactivity of members of the Metapneumovirus genus” [Virus Res. 105 (2004) 67–73]
  255. Human Metapneumovirus Persists in BALB/c Mice despite the Presence of Neutralizing Antibodies
  256. Anti–G Protein Antibody Responses to Respiratory Syncytial Virus Infection or Vaccination Are Associated with Inhibition of G Protein CX3C‐CX3CR1 Binding and Leukocyte Chemotaxis
  257. Serological cross-reactivity of members of the Metapneumovirus genus
  258. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles
  259. Pathogenesis of Respiratory Syncytial Virus Infection
  260. The Brume Surrounding Respiratory Syncytial Virus Persistence
  261. Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness
  262. Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P
  263. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice
  264. The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P
  265. Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection
  266. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection
  267. Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection
  268. Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helper–1 and T Helper–2 Cytokines and CC Chemokine Messenger RNA
  269. The Failure of Interleukin-10–deficient Mice to Develop Airway Hyperresponsiveness Is Overcome by Respiratory Syncytial Virus Infection in Allergen–sensitized/challenged Mice
  270. Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus
  271. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein
  272. 75th birthday of Professor Ralph Stock
  273. CD4+ T Cell Frequencies and Th1/Th2 Cytokine Patterns Expressed in the Acute and Memory Response to Respiratory Syncytial Virus I-Ed-Restricted Peptides
  274. Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse
  275. TH1- AND TH2-TYPE CYTOKINE EXPRESSION BY ACTIVATED TLYMPHOCYTES FROM THE LUNG AND SPLEEN DURING THE INFLAMMATORY RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS
  276. Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice
  277. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells
  278. Influenza Virus (Orthomyxovirus), Infection and Immunity
  279. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections
  280. Tuning into immunological dissonance: an experimental model for infectious mononucleosis
  281. Pathogenesis of an Infectious Mononucleosis-like Disease Induced by a Murine γ-Herpesvirus: Role for a Viral Superantigen?
  282. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
  283. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene
  284. Establishment and Persistence of Virus-Specific CD4+ and CD8+ T Cell Memory
  285. CD8+ T-cell memory to viruses
  286. Cortisol mediated suppression of salmonid lymphocyte responses invitro